- Home
- NBTX vs NCZ Comparison
NBTX vs NCZ Comparison
Compare NBTX & NCZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NBTX
- NCZ
- Stock Information
- Founded
- NBTX 2003
- NCZ 2003
- Country
- NBTX France
- NCZ United States
- Employees
- NBTX N/A
- NCZ N/A
- Industry
- NBTX Biotechnology: Pharmaceutical Preparations
- NCZ Finance Companies
- Sector
- NBTX Health Care
- NCZ Finance
- Exchange
- NBTX Nasdaq
- NCZ Nasdaq
- Market Cap
- NBTX 201.9M
- NCZ 240.5M
- IPO Year
- NBTX 2020
- NCZ N/A
- Fundamental
- Price
- NBTX $3.26
- NCZ $3.16
- Analyst Decision
- NBTX Strong Buy
- NCZ
- Analyst Count
- NBTX 1
- NCZ 0
- Target Price
- NBTX $12.00
- NCZ N/A
- AVG Volume (30 Days)
- NBTX 64.6K
- NCZ 533.0K
- Earning Date
- NBTX 12-31-2024
- NCZ 01-01-0001
- Dividend Yield
- NBTX N/A
- NCZ 12.16%
- EPS Growth
- NBTX N/A
- NCZ N/A
- EPS
- NBTX N/A
- NCZ N/A
- Revenue
- NBTX $45,220,186.00
- NCZ N/A
- Revenue This Year
- NBTX N/A
- NCZ N/A
- Revenue Next Year
- NBTX N/A
- NCZ N/A
- P/E Ratio
- NBTX N/A
- NCZ N/A
- Revenue Growth
- NBTX 526.17
- NCZ N/A
- 52 Week Low
- NBTX $2.76
- NCZ $2.50
- 52 Week High
- NBTX $8.96
- NCZ $3.15
- Technical
- Relative Strength Index (RSI)
- NBTX 42.55
- NCZ 36.19
- Support Level
- NBTX $3.18
- NCZ $3.22
- Resistance Level
- NBTX $3.69
- NCZ $3.29
- Average True Range (ATR)
- NBTX 0.27
- NCZ 0.06
- MACD
- NBTX 0.07
- NCZ -0.03
- Stochastic Oscillator
- NBTX 56.45
- NCZ 0.70
About NBTX Nanobiotix S.A.
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.
About NCZ Virtus Convertible & Income Fund II of Beneficial Interest
Virtus Convertible & Income Fund II is a diversified, closed-end management investment company. Its investment objective is to provide total return through a combination of capital appreciation and high current income. Its portfolio of investments includes different sector investments such as in healthcare services, media, oil, gas and consumable fuels and others.